Dimerix Limited is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in Chronic Kidney Disease will be announced to the ASX coincident with its feature as a poster presentation at the American Society of Nephrology (ASN) Kidney Week 2017, to be held in New Orleans, Louisiana […]
In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with Stuart Roberts, Senior Analyst with NDF Research.
The full interview is available here.
A recording of the public DMX-200 Phase 2a trial presentation and Q&A session is available below.
This presentation was held on 13 July 2017.
The corresponding presentation is available here.
Investors are invited to join a conference call to be hosted by Kathy Harrison, CEO at 12.00pm (AEST) on Thursday, 13th July 2017. The call will cover today’s release of positive Phase 2a clinical trial results from the DMX-200 program in patients with Chronic Kidney Disease.
To access the call: Dial 1800 […]
DMX-200 Phase 2a clinical trial meets primary safety endpoint and demonstrates encouraging efficacy in a clinically meaningful number of patients
- 25% of patients achieved a greater than 50% reduction in proteinuria, beyond that achieved with the highest dosage of current standard of care therapy
- 45% of […]
Dimerix CEO, Kathy Harrison will present at the Gold Coast Investment Showcase this morning.
The presentation is available here.
Dimerix today published a recorded interview with Chief Executive Officer Kathy Harrison.
The recent interview highlighted a number of important points including:
− the innovative clinical and commercial development pathway for Dimerix’s lead compound (DMX-200) as a potential new therapy for treating chronic kidney disease
− the global market size and significant unmet medical need for new kidney […]
Dimerix Limited today announced the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports.
Read the full announcement here.